跳至主要内容
临床试验/NCT00131287
NCT00131287已完成3 期

The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)

ECbiotech Taiwan2 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2005年7月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
108
试验地点
2
主要终点
Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR)

研究概览

简要总结

The purpose of this study is to examine whether the extract of the Agaricus blazei Murill mushroom is effective in the supplementary treatment of type II DM patients.

详细描述

The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom is effective in the treatment of type II DM mice conducted on 2002. The dose effects were also found. The researchers conducted the pilot study also showing the same effects in 2003. So the researchers designed this trial. The elixir of the Agaricus blazei Murill mushroom is popular in Taiwan for chronic diseases, such as type II DM.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type II DM
  • Age 20-75 years old
  • Treat with Gliclazide and Metformin
  • Signed informed consent

排除标准

  • GOT/GPT >80/80
  • Creatinine > 2.0
  • Lactating or pregnant women

结局指标

主要结局

Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR)

次要结局

  • Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons

研究者

发起方
ECbiotech Taiwan
申办方类型
Other

研究点 (2)

Loading locations...

相似试验